Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

NCT00765830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

349

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Renal Insufficiency

Interventions

DRUG: vildagliptin
DRUG: Placebo

Sponsor

Novartis